Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5954 - Clinical utility of plasma cell-free DNA in patients with pancreatic cancer.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Pancreatic Cancer

Presenters

Inna Chen

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

I. Chen1, K.L. Wind2, C. Dehlendorff3, B.S. Sørensen4, B.V. Vittrup1, A. Johansen1, P. Pfeiffer5, J.K. Bjerregaard5, S.E. Bojesen6, S.E. Nielsen7, N.H. Holländer8, M.K. Yilmaz9, L.S. Rasmussen9, N. Pallisgaard10, J.S. Johansen1, K.G. Spindler4

Author affiliations

  • 1 Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 2 Department Of Clinical Oncology, Aarhus University Hospital, 8000 - Aarhus/DK
  • 3 Statistics And Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen/DK
  • 4 Experimental Clinical Oncology, Aarhus University Hospital, 8000 - Aarhus/DK
  • 5 Experimental Research In Medical Cancer Therapy, Odense University Hospital, 5000 - Odense C/DK
  • 6 Department Of Clinical Biochemistry, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 7 Department Of Oncology, North Zealand University Hospital, 3400 - Hillerød/DK
  • 8 Department Of Oncology, Zealand University Hospital in Næstved, 4180 - Næstved/DK
  • 9 Department Of Oncology, Aalborg University Hospital, Aalborg/DK
  • 10 Department Of Pathology, Zealand University Hospital in Roskilde, 4000 - Roskilde/DK
More

Resources

Abstract 5954

Background

Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.

Methods

A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R&D), interleukin-6 (IL-6) (ELISA, R&D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

Results

Pts with PC had significantly higher level of plasma cfDNA (median (range): 1.15 [0.45, 4.94] ng/uL) compared with healthy subjects (0.52 [0.48, 0.57] ng/uL, ROC analysis AUC 0.89). The level of plasma cfDNA was significantly increased with advanced stage, presence of liver metastases and worse Performance Status (PS). When analyzed as a continuous parameter, cfDNA higher than median of 1.15 ng/uL alone was associated with reduced OS (HR = 1.40, 95% CI 1.13-1.72, P = 0.002) in univariate analyses along with age >50, worse PS, higher stage, presence of liver metastases, and log2-transformed serum levels of CA19-9, HA, IL-6 and YKL-40. In multivariate analysis, plasma cfDNA (median and 75% quartile as cutoff) was not statistically significantly associated with OS, but CA19-9 and IL-6 along with higher age, PS, stage and presence of liver metastases were associated with shorter OS.

Conclusions

Plasma cfDNA concentrations measured with a simple assay was higher in PC patients than in healthy individuals. High plasma cfDNA levels were associated with a short OS. Adjusted for a number of known prognostic parameters cfDNA was not statistically significantly associated with OS.

Clinical trial identification

Legal entity responsible for the study

Julia Sidenius Johansen.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.